|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
177,680,000 |
Market
Cap: |
8.86(B) |
Last
Volume: |
6,014,710 |
Avg
Vol: |
1,940,342 |
52
Week Range: |
$50.38 - $99.04 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 568 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
53,111 |
108,398 |
168,494 |
290,334 |
Total Sell Value |
$3,153,997 |
$6,570,910 |
$11,439,131 |
$18,676,003 |
Total People Sold |
10 |
10 |
11 |
11 |
Total Sell Transactions |
27 |
52 |
62 |
100 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Herriott James |
General Counsel |
|
2024-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
581 |
7,524 |
|
- |
|
Condella Sarah |
EVP, Human Resources |
|
2024-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,034 |
73,692 |
|
- |
|
Condella Sarah |
EVP, Human Resources |
|
2024-02-21 |
4 |
AS |
$61.50 |
$66,359 |
D/D |
(1,079) |
71,658 |
|
-21% |
|
Conroy Kevin T |
President and CEO |
|
2024-02-21 |
4 |
AS |
$61.50 |
$305,963 |
D/D |
(4,975) |
1,229,756 |
|
-21% |
|
Baranick Brian |
Gen. Mgr., Precision Oncology |
|
2024-02-21 |
4 |
AS |
$61.50 |
$55,043 |
D/D |
(895) |
8,826 |
|
-21% |
|
Coward D Scott |
Director |
|
2024-02-21 |
4 |
AS |
$61.50 |
$43,419 |
D/D |
(706) |
43,122 |
|
-21% |
|
Elliott Jeffrey Thomas |
Chief Financial Officer |
|
2024-02-21 |
4 |
AS |
$61.50 |
$91,820 |
D/D |
(1,493) |
3,703 |
|
-21% |
|
Orville Jacob A |
General Manager, Screening |
|
2024-02-21 |
4 |
AS |
$61.50 |
$66,297 |
D/D |
(1,078) |
8,658 |
|
-21% |
|
Herriott James |
General Counsel |
|
2024-02-21 |
4 |
AS |
$61.50 |
$25,523 |
D/D |
(415) |
6,943 |
|
-21% |
|
Condella Sarah |
EVP, Human Resources |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,248 |
72,737 |
|
- |
|
Conroy Kevin T |
President and CEO |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,374 |
1,234,731 |
|
- |
|
Baranick Brian |
Gen. Mgr., Precision Oncology |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,729 |
9,721 |
|
- |
|
Coward D Scott |
Director |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,248 |
43,828 |
|
- |
|
Elliott Jeffrey Thomas |
Chief Financial Officer |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,112 |
5,196 |
|
- |
|
Orville Jacob A |
General Manager, Screening |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,248 |
9,736 |
|
- |
|
Herriott James |
General Counsel |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
864 |
7,358 |
|
- |
|
Coward D Scott |
Director |
|
2024-02-15 |
4 |
AS |
$61.43 |
$84,528 |
D/D |
(1,376) |
41,580 |
|
-18% |
|
Herriott James |
General Counsel |
|
2024-02-15 |
4 |
AS |
$61.43 |
$25,862 |
D/D |
(421) |
6,494 |
|
-18% |
|
Elliott Jeffrey Thomas |
Chief Financial Officer |
|
2024-02-15 |
4 |
AS |
$61.43 |
$115,980 |
D/D |
(1,888) |
2,084 |
|
-18% |
|
Condella Sarah |
EVP, Human Resources |
|
2024-02-15 |
4 |
AS |
$61.43 |
$59,280 |
D/D |
(965) |
70,489 |
|
-18% |
|
Orville Jacob A |
General Manager, Screening |
|
2024-02-15 |
4 |
AS |
$61.43 |
$59,341 |
D/D |
(966) |
7,488 |
|
-18% |
|
Conroy Kevin T |
President and CEO |
|
2024-02-15 |
4 |
AS |
$61.43 |
$908,611 |
D/D |
(14,791) |
1,224,357 |
|
-18% |
|
Coward D Scott |
Director |
|
2024-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,972 |
42,956 |
|
- |
|
Herriott James |
General Counsel |
|
2024-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
883 |
6,915 |
|
- |
|
Elliott Jeffrey Thomas |
Chief Financial Officer |
|
2024-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,972 |
3,972 |
|
- |
|
777 Records found
|
|
Page 3 of 32 |
|
|